Inflammatory bowel disease: Immunodiagnostics, immunotherapeutics, and ecotherapeutics

Gastroenterology

Volumn 120, Issue 3, 2001, Pages 622-635

  Shanahan, Fergus ^a  

^a University College Cork and INFANT Centre   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID; PROBIOTIC AGENT;

BLOOD TOXICITY; DISEASE MARKER; DRUG EFFICACY; DRUG INDUCED DISEASE; ENTERITIS; GASTROINTESTINAL SYMPTOM; GENE THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; SERODIAGNOSIS;

EID: 0035116091     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2001.22122     Document Type: Article

References (124)

1. Mechanisms of immunologic sensation of intestinal contents
2. Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease
3. Inflammatory bowel disease: Etiology and pathogenesis
4. Commensal bacteria as targets in Crohn's disease
5. Induction and modulation of gastrointestinal inflammation
6. Therapy of inflammatory bowel disease
7. Biologic therapy for inflammatory bowel disease
8. Cytokine-based therapies in inflammatory bowel disease
9. Probiotics and inflammatory bowel disease: Is there a scientific rationale?
10. Bacterial regulation of intestinal immune responses
11. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease
12. Discovering the cause of inflammatory bowel disease: Lessons from animal models
13. Antibody 'markers' in Crohn's disease: Opportunity or overstatement?
14. Relationship of extraintestinal involvements in inflammatory bowel disease. New insights into autoimmune pathogenesis
15. Immunologic and genetic links in Crohn's disease
16. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease
17. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: Prevalence and diagnostic role
18. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease
19. Serologic testing for inflammatory bowel disease
20. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup
21. Immunological tests to monitor inflammatory bowel disease - Have they delivered yet?
22. Acute phase proteins and other systemic responses to inflammation
23. New insights into the biology of the acute phase response
24. Tumour necrosis factor a and interleukin-1b in relapse of Crohn's disease
25. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease
26. Azathioprine: An update on clinical efficacy and safety in inflammatory bowel disease
27. Azathioprine: State of the art in inflammatory bowel disease
28. New therapeutic approaches to Crohn's disease
29. Immunosuppressors for inflammatory bowel disease: How long is long enough?
30. Mesalamine for the prevention of postoperative recurrence: Is nearly there the same as being there?
31. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European cooperative Crohn's disease study VI
32. A comparison of methotrexate with placebo for the maintenance of remission of Crohn's disease
33. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease
34. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease
35. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine
36. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
37. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease
38. Infliximab is the drug we have been waiting for in Crohn's disease
39. Infliximab for the treatment of fistulas in patients with Crohn's disease
40. The relationship between infliximab treatment and lymphoma in Crohn's disease
41. Lymphoma in inflammatory bowel disease
42. Extracolonic malignancies in inflammatory bowel disease
43. Crohn's disease and cancer: A population-based cohort study
44. Thalidomide on the comeback trail
45. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
46. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
47. Thalidomide therapy for Crohn's disease
48. CC-3052: A water soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production
49. Viral vectors expressing immunoregulatory cytokines to treat inflammatory bowel disease
50. Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease
51. Interleukin 10 gene transfer prevents experimental colitis in rats
52. Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kB super-repressor in human intestinal epithelial cells
53. Perioral gene therapy of lactose intolerance using an adeno-associated virus vector
54. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy
55. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis
56. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance
57. Blockade of interleukin 6 trans signalling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn's disease and experimental colitis in vivo
58. A preliminary study of growth hormone therapy for Crohn's disease
59. Growth hormone as an immunomodulating therapeutic agent
60. Enhanced survival and mucosal repair following DSS colitis in transgenic mice that overexpress bovine growth hormone
61. Treatment of chronic inflammatory bowel disease in glycogen storage disease type 1b with colony-stimulating factors
62. Cyclic neutropenia in Crohn's ileocolitis: Effiicacy of granulocyte colony-stimulating factor
63. Treatment of fistulas with granulocyte colony-stimulating factor in a patient with Crohn's disease
64. Immunostimulation in Crohn's disease: Results of a pilot study of G-CSF (R-Methug-CSF) in mucosal and fistulizing Crohn's disease
65. Increased mucosal production of granulocyte colony-stimulating factor is related to a delay in neutrophil apoptosis in inflammatory bowel disease
66. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response
67. Differentiation and reversal of malignant changes in colon cancer through PPARγ
68. MMPs in the gut: Inflammation hits the matrix
69. Imbalance of stromolysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease
70. A major role of matrix metalloproteinases in T cell injury in the gut
71. Suppression of T cell-mediated injury in human gut by interleukin 10: Role of matrix metalloproteinases
72. Pharmacogenomics and metabolite measurement of 6-mercaptopurine therapy in inflammatory bowel disease
73. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low
74. Tumor necrosis factor (TNF) microsatellite haplotypes and perinuclear anti-neutrophil cytoplasmic antibody (pANCA) identify Crohn's disease (CD patients with poor clinical responses to anti-TNF monoclonal antibody (cA2)
75. Evaluation of TNF microsatellites and SNPS in a cohort of chronic active, therapy refractory Crohn's disease patients treated with anti-TNF alpha
76. ASCA and PANCA do not predict response to anti-TNFA (Remicade®) treatment
77. Response to anti-TNFA treatment is associated with the TNFA-308*1 allele
78. Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease
79. Th2 conditioning by Trichuris suis appears safe and effective in modifying the mucosal immune response in inflammatory bowel disease
80. The indigenous gastrointestinal microflora
81. Microbe-host interactions in the alimentary tract: The gateway to understanding inflammatory bowel disease
82. The role of the fecal stream in Crohn's disease: An historical and analytical review
83. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum
84. Role of the faecal stream in the maintenance of Crohn's colitis
85. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum
86. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD)
87. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12
88. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria
89. T cell specificity and cross reactivity toward enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans
90. + T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: Increased T helper cell type 1 response and ability to transfer disease
91. Medical therapy for induction and maintenance of remission in pouchitis: A systematic review
92. The neglected organ: Bacterial flora has a crucial immunostimulatory role
93. Antibiotics are not effective therapy for Crohn's disease (time to remove the rose-coloured glasses)
94. Antibiotics are effective therapy for Crohn's disease
95. Probiotics
96. Functional foods and health promotion
97. Functional food science and gastrointestinal physiology and function
98. Probiotics, prebiotics or "conbiotics"?
99. The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acid-induced colitis in the rat
100. The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats
101. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice
102. A controlled trial of probiotic treatment of IL-10 knockout mice
103. Evaluation and characterisation of probiotic therapy in the CD45RBhi transfer model of colitis
104. Immunity and probiotics
105. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis
106. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial
107. Probiotic therapy with E. coli for ulcerative colitis: Take the good with the bad
108. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double blind, placebo-controlled trial
109. Ecological control of the gastrointestinal tract. The role of probiotic flora
110. Epithelial cell growth and differentiation III. Promoting diversity in the intestine: Conversations between the microflora, epithelium, and diffuse GALT
111. Stimulation of transforming growth factor-b1 by enteric bacteria in the pathogenesis of rat intestinal fibrosis
112. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures
113. Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats
114. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10
115. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation
116. Therapeutic manipulation of gut flora
117. Identification of a novel bacterial sequence associated with Crohn's disease
118. Why graduate medical schools make sense
119. An international survey of the use and attitudes regarding alternative medicine by patients with inflammatory bowel disease
120. Presidential address: Gastrointestinal illness and the biopsychosocial model
121. The gastrointestinal system and psychological factors
122. Brain-gut axis and mucosal immunity: A perspective on mucosal psychoneuroimmunology
123. + lymphocytes in the susceptibility of mice to stress-induced reactivation of experimental colitis
124. Anti-TNF therapy for Crohn's disease: A perspective (infliximab is not the drug we have been waiting for)